Abstract

Neutralizing human monoclonal antibodies (mAbs) against SARS-CoV-2 require Fc effector functions for optimal protection during post-exposure therapy, with intact mAbs reducing SARS-CoV-2 burden and lung disease in rodent models better than LALA-PG loss-of-function Fc variant mAbs and requiring monocytes and CD8+ T cells for optimal clinical and virological benefit.

Original languageEnglish
Pages (from-to)1804-1820.e16
JournalCell
Volume184
Issue number7
DOIs
StatePublished - Apr 1 2021

Keywords

  • CD8+ T cells
  • RNA sequencing
  • SARS-CoV-2
  • antibody
  • effector function
  • lung
  • monocytes
  • mouse model
  • pathogenesis
  • therapy

Fingerprint

Dive into the research topics of 'Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection'. Together they form a unique fingerprint.

Cite this